Long-term safety of an extended-cycle oral contraceptive (Seasonale): A 2-year multicenter open-label extension trial

American Journal of Obstetrics and Gynecology

Volumn 195, Issue 1, 2006, Pages 92-96

  Anderson, F D ^a   Gibbons, William ^a   Portman, David ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Columbus Center for Women's Health Research ^*  (United States)

Author keywords

Extended cycle; Extended regimen; Oral contraceptive; Seasonale

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ALLERGIC REACTION; ARTICLE; BACKACHE; BLEEDING; CLINICAL TRIAL; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; FLU LIKE SYNDROME; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MENORRHAGIA; MENSTRUAL CYCLE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SAFETY; SIDE EFFECT; SINUSITIS; SORE THROAT; SPOTTING; TIME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CYTOLOGY; VAGINITIS;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL-NORGESTREL COMBINATION; FEMALE; HUMANS; MENSTRUATION;

EID: 33745239286     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.12.045     Document Type: Article

References (20)

1. Wiegratz I., Hommel H.H., Zimmermann T., and Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 69 (2004) 37-42
2. Sulak P.J., Kuehl T.J., Ortiz M., and Shull B.L. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
3. Kaunitz A.M. Menstruation: choosing whether and when. Contraception 62 (2000) 277-284
4. Anderson F.D., and Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 68 (2003) 89-96
5. Anderson F.D., Hait H., Hsiu J., Thompson-Graves A.L., Wilborn W.H., and Williams R.F. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 71 (2005) 55-59
6. Miller L., and Notter K.M. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 98 (2001) 771-778
7. Sulak P.J., Cressman B.E., Waldrop E., Holleman S., and Kuehl T.J. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 89 (1997) 179-183
8. Willis S.A., Kuehl T.J., and Spiekerman A.M. Effects of shortened hormone-free interval in cycles of oral contraceptive pills on pituitary-ovarian axis. Fertil Steril 82 Suppl 2 (2004) S107
9. Kwiecien M., Edelman A., Nichols M.D., and Jensen J.T. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 67 (2003) 9-13
10. Belsey E.M., Machin D., and d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34 (1986) 253-260
11. Darney P.D. OC practice guidelines: minimizing side effects. Int J Fertil Womens Med Suppl 1 (1997) 158-169
12. Thijs C., and Knipschild P. Oral contraceptives and the risk of gallbladder disease: a meta-analysis. Am J Public Health 83 (1993) 1113-1120
13. Boland L.L., Folsom A.R., Rosamond W.D., and Atherosclerosis Risk in Communities Study I. Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease. A prospective study. Ann Epidemiol 12 (2002) 131-140
14. Everhart J.E., Khare M., Hill M., and Maurer K.R. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 117 (1999) 632-639
15. de Bruijn S.F., Stam J., and Vandenbroucke J.P. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet 351 (1998) 1404
16. Kemmeren J.M., Tanis B.C., van den Bosch M.A., Bollen E.L., Helmerhorst F.M., Algra A., et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 33 (2002) 1202-1208
17. Lidegaard O., Edstrom B., and Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 65 (2002) 187-196
18. Sidney S., Petitti D.B., Soff G.A., Cundiff D.L., Tolan K.K., and Quesenberry Jr. C.P. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 70 (2004) 3-10
19. Bagwell M.A., Thompson S.J., Addy C.L., Coker A.L., and Baker E.R. Primary infertility and oral contraceptive steroid use. Fertil Steril 63 (1995) 1161-1166
20. Bracken M.B., Hellenbrand K.G., and Holford T.R. Conception delay after oral contraceptive use: the effect of estrogen dose. Fertil Steril 53 (1990) 21-27